Supplementary Table 1 C min of Teicoplanin at 1 st and 2 nd TDM in patients with administration of additional loading dose on the 4 th day Teicoplanin.

Slides:



Advertisements
Similar presentations
Procalcitonin Over the past two decades, the body of literature on the clinical usefulness of procalcitonin (PCT) in adults has grown rapidly. Although.
Advertisements

National Institute for Health and Clinical Excellence.
Table 1. Comparison between the provisional diagnosis based on the proforma versus final diagnosis Early arthritis Rheumatoid arthritis 3 6 Psoriatic.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
CREATININE AND CYSTATIN-C BASED GFRs VS 51 Cr-EDTA GFR IN PATIENTS WITH DECOMPENSATED CIRRHOSIS 1 4th Department of Internal Medicine, Hippokration General.
Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
Renal Diseases. Kidney Failure Kidney failure is also called renal failure. With kidney failure, the kidneys cannot get rid of the body’s extra fluid.
Pharmacotherapy in the Elderly Judy Wong
1 25th ECCMID , Munich, Germany Magnitude of bacteremia predicts one-year mortality Kim O. Gradel 1, Henrik C. Schønheyder 1,2, Mette Søgaard 1,
C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.
Non-Surgical Periodontal Therapy Reduces Coronary Heart Disease Risk Markers: A Randomized Controlled Trial Bokhari SAH, Khan AA, Butt AK, Azhar M, Hanif.
Dose Adjustment in Renal and Hepatic Disease
Intensive versus Conventional Glucose Control in Critical Ill Patients N Engl J Med 2009; 360: 雙和醫院 劉慧萍藥師.
MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII INFECTION IN RESPIRATORY INTENSIVE CARE UNIT Pervin Korkmaz Ekren 1, M. Sezai Tasbakan 1, Burcu Basarık 1,
Optimizing Nutrition Therapy
Clinical Pharmacy Part 2
Comparison of the Systemic Inflammatory Response Syndrome between Monomicrobial and Polymicrobial Pseudomonas aeruginosa Nosocomial Bloodstream Infections.
Terry White, MBA, BSN SEPSIS. SIRS Systemic Inflammatory Response System SIRS is a widespread inflammatory response to a variety of severe clinical injuries.
ARDS: how are we doing? Martin Hughes September 2010.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
A Retrospective Study of Outcomes in Pediatric Hematology/Oncology Patients Receiving Continuous Venovenous Hemodialysis Y Avent 1, N Henderson 1, T Collie.
Nursing Management: Shock and Multiple Organ Dysfunction Syndrome
Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications FactorUnivariate RR (95% CI)P-valueMultivariate RR *1.
Author Name: Kannika Inpra Presenter Name: Kannika Inpra Authors: Inpra K., Suwankesawong W., Kaewvichit S. Institution: Phrae.
References Results Methods Purpose Risk Factors and Clinical Courses of Acute Kidney Injury in Patients with Femur Fracture Seung-Jee Ryu*, Young-Ok Kim*,
Plasma soluble receptor for advanced glycation end products (sRAGE) predicts survival in critically ill patients with systemic inflammatory response syndrome.
Immunisation overview ST1 Sept 09 Dr Ulla Trend. The two public health interventions with the greatest impact are clean water and immunisation (World.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
Association of C-Reactive Protein and Acute Myocardial Infarction in HIV-Infected Patients Virginia A. Triant, MD, MPH, James B. Meigs, MD, MPH, and Steven.
The Association between blood glucose and length of hospital stay due to Acute COPD exacerbation Yusuf Kasirye, Melissa Simpson, Naren Epperla, Steven.
Bicarbonate-Based Solutions in the Management of Acute Kidney Injury Vania Cecilia Prudencio-Ribera, MD 1 ; Universidad Mayor de San Simón, School of Medicine,
Sepsis Dr John Green. Definitions Infection – An inflammatory response to microorganisms or the presence of microorganisms in normally sterile tissue.
Diabetic nephropathy is a clinical syndrome.
Raghavan Murugan, MD, MS, FRCP Associate Professor of Critical Care Medicine, and Clinical & Translational Science Core Faculty, Center for Critical Care.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
INTRODUCTION CLINICAL PHARMACOKINETICS
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
CH. 5 GOODMAN. CH.5  “Many conditions and diseases seen in the rehabilitation setting can affect multiple organs or systems.”
Therapeutic drug Monitoring
1 NDA Clofarabine Cl-F-Ara-A Presented by Martin Cohen, M.D. at the December 01, 2004 meeting of the Oncologic Drugs Advisory Committee meeting.
An unpleasant sensory or emotional experience associated with actual or potential tissue damage The World Health Organization (WHO) has stated that pain.
Date of download: 5/28/2016 From: New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study Ann Intern Med. 2012;156(8):
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney.
Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Outcomes Associated With Microalbuminuria: Effect.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching.
Adequacy of beta-lactam antibiotic dosing in critically ill children on continuous renal replacement therapy: A pilot study. Diaz F 1,2, Benner KW 3, Sewell.
Utility of Procalcitonin concentration in the evaluation of patients with malignant diseases and elevated c- reactive protein plasma concentration Silke.
Table S1. Logistic regression analysis for the variables associated with the degree of change in cTnT between 2 time points (n=89) UnivariateMultivariate.
Date of download: 7/1/2016 From: Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2015;162(4):
1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.
Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht.
From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.
FIGURE 1 Flow chart of the study population
Results of a kidney-protection strategy during open thoracoabdominal aortic surgery according to RIFLE criteria.
by Qi Sun, Monik C. Jiménez, Mary K. Townsend, Eric B. Rimm, JoAnn E
Associations of renal impairment (adjusted odds ratio and 95% CI) and the presence of individual small vessel disease markers stratified by age. Associations.
Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Volume 93, Issue 4, Pages (April 2018)
B. Beović, S. Kreft, J. Osredkar, D. Keše, B. Bonač-Tuma 
بنام خداوند جان و خرد بنام خداوند جان و خرد.
Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia  F.M. Brunkhorst, B. Al-Nawas, F. Krummenauer,
Therapeutic Drug Monitoring chapter 1 part 1
Voriconazole concentrations and outcome of invasive fungal infections
Validation of the Oxford classification of IgA nephropathy
Urban–Rural Comparisons in Hospital Admission, Treatments, and Outcomes for ST-Segment–Elevation Myocardial Infarction in China From 2001 to 2011 A Retrospective.
Kaplan-Meier curve for the probability of noninvasive ventilation (NIV) failure relative to continuous use of NIV and stratified for Acute Physiology and.
Presentation transcript:

Supplementary Table 1 C min of Teicoplanin at 1 st and 2 nd TDM in patients with administration of additional loading dose on the 4 th day Teicoplanin C min Conventional loading regimen (n=25) Enhanced loading regimen (n=16) C min at initial TDM Median (IQR, Range) (µg/mL)9.7 ( , )12.3 ( , ) No. of patients with < 10 µg/mL (rate)13 (52.0%)2 (12.5%) No. of patients with µg/mL (rate)12 (48.0%)14 (87.5%) No. of patients with µg/mL (rate)0 (0.0%) No. of patients with >30 µg/mL (rate)0 (0.0%) C min at secondary TDM Median (IQR, Range) (µg/mL)14.9 ( , )18.8 ( , ) No. of patients with < 10 µg/mL (rate)2 (8.0%)0 (0.0%) No. of patients with µg/mL (rate)11 (44.0%)2 (12.5%) No. of patients with µg/mL (rate)12 (48.0%)14 (87.5%) No. of patients with >30 µg/mL (rate)0 (0.0%) C min : trough concentration, TDM: therapeutic drug monitoring, IQR: Interquartile range

Supplementary Table 2 Fulfillment of the criteria of each factor included in the definition of clinical success Factors for definitionNo of patients who met the definition of clinical success at the end of therapy (rate) Each factorClinical success Inflammatory biomarker (CRP/PCT) 75 * /106 (70.8%) 68 (64.2%) Peripheral white blood cell count 85/106 (80.2%) Body temperature 84/106 (79.2%) Clinical features 75/106 (70.8%) X-ray 38/58 ** (67.9%) CRP: C-reactive protein, PCT: procalcitonin, * : Fulfillment of criteria in PCT was observed in 15 patients who failed to meet the criteria of CRP ** : Patients with respiratory tract infections, intraabdominal infections, and mediastinitis

Supplementary Table 3 Fulfillment of the criteria of each factor included in the definition of clinical improvement on the 4 th day of therapy Factors for definition No of patients who met the definition of clinical improvement on the 4 th day (rate) Each factorClinical improvement Inflammatory biomarker (CRP/PCT) 76 * /106 (71.7%) 83/106 (78.3%) 67/106 (63.2%) Peripheral white blood cell count 33/106 (31.1%) Body temperature 68/90 ** (75.6%) Clinical features 77/106 (72.6%) * : Fulfillment of criteria in PCT was observed in 2 patients who failed to meet the criteria of CRP, ** : Sixteen patients were afebrile at the start of therapy

Supplementary Table 4. Clinical success rate in patients who achieved initial and maximal C min of >15 µg/mL and in those that did not in conventional and enhanced loading regimens regimen No of patients with clinical success (rate) initial C min Maximal C min >15 µg/mL<15 µg/mLP-value>15 µg/mL<15 µg/mLP-value Conventional regimen6/6 (100%)17/32 (53.1%) /16 (81.3%)10/22 (45.5%)0.026 Enhanced loading regimen39/54 (72.2%)6/14 (42.9%) /59 (71.2%)3/9 (33.3%)0.052 C min : trough concentration

Factors No of patients with clinical success at the end of therapy (%) P-value Crude odds ratio (95%CI) Adjusted odds ratio (95%CI) Patients with factorPatients without factor Sex (male)48/75 (64.0%)20/31 (64.5%) ( )- Age (>65 years)48/74 (64.9%)20/32 (62.5%) ( )- eGFR<40mL/min/1.73m230/47 (63.8%)38/59 (64.4%) ( )- Heart disease26/42 (61.9%)42/64 (65.6%) ( )- Chronic renal failure18/28 (64.3%)50/78 (64.1%) ( )- Diabetes mellitus23/35 (65.7%)45/71 (63.4%) ( )- Collagen disease6/11 (54.5%)62/95 (65.3%) ( )- Chronic respiratory disease4/8 (50.0%)64/98 (65.3%) ( )- Inflammatory bowel disease5/7 (71.4%)63/99 (63.6%) ( )- Intensive care unit stay (>3 days)10/19 (52.6%)58/87 (66.7%) ( )- Immunosuppressive therapy2/4 (50.0%)66/102 (64.7%) ( )- Liver cirrhosis/chronic hepatic dysfunction14/27 (51.9%)54/79 (68.4%) ( )- Malignant tumor25/48 (52.1%)43/58 (74.1%) ( )0.18 ( ) Malnutrition31/54 (57.4%)37/52 (71.2%) ( )- Total parenteral nutrition15/31 (48.4%)53/75 (70.7%) ( )- Ventilator use6/16 (37.5%)62/90 (68.9%) ( )0.26 ( ) APACHE II score > 11 (median)25/55 (45.5%)43/51 (84.3%)< ( )0.12 ( ) Surgery within 28 days33/46 (71.7%)35/60 (58.3%) ( )- Steroid use12/23 (52.2%)56/83 (67.5%) ( ) 0.34 ( ) Anticancer therapy5/17 (29.4%)63/89 (70.8%) ( )- Blood infections13/26 (50.0%)55/80 (68.8%) ( )- Skin & soft tissue infections18/22 (81.8%)50/84 (59.5%) ( )- Osteomyelitis and arthritis2/7 (28.6%)66/99 (66.7%) ( ) 0.01 ( ) Urinary tract infection5/2 (100%)63/101 (62.4%) Other typr of infections0/2 (0%)68/104 (65.4%) Respiratory infection24/40 (60.0%)44/66 (66.7%) ( )- Intra-abdominal infection11/16 (68.8%)57/90 (63.3%) ( )- Mixed infection with Gram-negative organisms38/64 (59.4%)30/42 (71.4%) ( )- Therapy for definitive or presumed fungal infections7/13 (53.8%)61/93 (65.6%) ( )- Enhanced loading regimen45/68 (66.2%)23/38 (60.5%) ( )- Teicoplanin initial C min ≥15 μg/mL45/60 (75.0%)23/46 (50.0%) ( )4.20 ( ) Teicoplanin maximal C min ≥15 μg/mL55/75 (73.3%)13/31 (41.9%) ( )2.88 ( ) Supplementary Table 5. Variable associated with clinical success at the completion of teicoplanin therapy: univariate and multivariate analysis. eGFR: estimated glomerular filtration rate, APACHE II : Acute physiology and chronic health evaluation II score